BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Colorcon
US Department of Justice
Mallinckrodt
Federal Trade Commission
Express Scripts
Moodys
McKinsey
Fish and Richardson

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,247,400

« Back to Dashboard

Which drugs does patent 8,247,400 protect, and when does it expire?

Patent 8,247,400 protects TEFLARO and is included in one NDA.

This patent has two patent family members in two countries.
Summary for Patent: 8,247,400
Title:Cephem compounds useful for the treatment of bacterial infections
Abstract: The present invention relates to new cephem compounds useful for the treatment of bacterial infections of formula I: ##STR00001## The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly well suited for, e.g., parenteral administration for the treatment of bacterial infections.
Inventor(s): Dedhiya; Mahendra G. (Pomona, NY), Singh; Brahma N. (Syosset, NY)
Assignee:
Application Number:12/710,417
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,247,400

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cerexa TEFLARO ceftaroline fosamil POWDER;IV (INFUSION) 200327-001 Oct 29, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y METHOD OF TREATING BACTERIAL INFECTIONS ➤ Subscribe
Cerexa TEFLARO ceftaroline fosamil POWDER;IV (INFUSION) 200327-002 Oct 29, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y METHOD OF TREATING BACTERIAL INFECTIONS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Chinese Patent Office
Citi
Medtronic
McKinsey
UBS
Queensland Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot